Hypertriglyceridemia - Redemplo
Customize your policy alerts
Sign up for Cigna Policy IP0773 alerts
Get alerted when Policy IP0773 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Redemplo (plozasiran subcutaneous injection) in adults with familial chylomicronemia syndrome. It applies to health benefit plans administered by Cigna Companies, subject to the applicable benefit plan terms and coverage mandates.
The approval duration for initial Redemplo therapy was changed from 1 year to 6 months.
Continuation therapy was added for patients currently receiving Redemplo who have experienced a response to therapy.
The preferred-product requirement for a prior Tryngolza trial was removed.
The terminology describing decreased platelets was replaced with thrombocytopenia.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.